Goal

The Ototoxicity prevention program is evaluating oral and intravenous compounds in R&D for the prevention of drug-induced ototoxicity.

The focus of this program is to:

  • Reduce hearing loss induced by cisplatin toxicity
  • Avoid any interference with the use and effectiveness of cisplatin during chemotherapy

Cisplatin-induced Ototoxicity

Platinum-based agents such as cisplatin, carboplatin and oxaliplatin, alone or in combination, are often used to treat a wide variety of cancers. However, they have common and often severe adverse effects including:

  • Renal toxicity
  • Hematological or gastrointestinal trauma
  • Ototoxicity leading to hearing loss and tinnitus

Cisplatin specifically is used in 25% of primary chemotherapeutic treatment of various cancers. Hearing loss with cisplatin is:

  • Seen in more than 30% of adults
  • Observed to varying degrees in >70% of treated children
  • Progressive, worsening with each successive chemotherapy cycle
  • Irreversible

 

References:
Rybak et al., (2009) Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies. Tohoku J Exp Med. 219(3): 177–186. Pubmed

Latest news

  • 21 May 2020

    Sensorion publishes results of General Assembly resolutions. Read

  • 29 Apr 2020

    Sensorion announces it will hold its General Assembly on May 20, 2020 behind closed doors alongside the publication of its 2019 annual financial report. Read

Patient center

Corporate presentation